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Summary
Tumorigenesis results from events that impinge on a variety of collaborating metabolic pathways. To assess their role in
this process, we utilized a cell-based assay to perform a high-throughput, chemical library screen. In so doing, we identified
F16, a small molecule that selectively inhibits proliferation of mammary epithelial, neu-overexpressing cells, as well as a
variety of mouse mammary tumor and human breast cancer cell lines. F16 belongs to a group of structurally similar
molecules with a delocalized positive charge. The compound is accumulated in mitochondria of responsive cells, driven
by the membrane potential, and it compromises their functional integrity. Mitochondrial hyperpolarization is a shared
feature of many tumor cell lines, explaining the broad action spectrum of this novel delocalized lipophilic cation.
Introduction prompted the development of reagents that directly affect
HER-2 activity as a means to interfere with tumor cell growth.
The HER-2/erbB-2/neu proto-oncogene is a member of the The search for small molecules that act as ATP competitive
epidermal growth factor (EGF) receptor family. This group of inhibitors and natural tyrosine kinase inhibitors has yielded sev-
receptor tyrosine kinases plays an essential role during growth eral compounds still under development (Noonberg and Benz,
and differentiation of many tissues, and its overexpression is 2000; Seymour, 2001; Zwick et al., 2001). Neutralizing mono-
associated with several types of human cancers (Hynes and clonal antibodies directed against the extracellular domain of
Stern, 1994; Olayioye et al., 2000; Rubin and Yarden, 2001). HER-2 have also been shown to reduce HER-2 protein level
Among human breast cancers, the HER-2 gene is amplified and and kinase activity. Herceptin, the humanized recombinant
the protein overexpressed in 20%–30% of cases, and this event version of the mouse monoclonal 4D5, is currently being used
correlates with poor prognosis (Yarden, 2001). Targeted expres- for the treatment of patients with HER-2-overexpressing breast
sion of constitutively active neu, the HER-2 rat oncogenic allele, tumors with significant, yet limited, clinical efficacy. This anti-
to the mouse mammary gland induces the appearance of body holds out promising results when used in combination
multifocal mammary tumors in females harboring the transgene therapies rather than as a first line-single agent therapeutic
(Muller et al., 1988). Furthermore, HER-2 antisense treatment (Baselga, 2001; Winer and Burstein, 2001). Even though the
in HER-2-overexpressing cells leads to an increase in apoptosis, mechanism of action of Herceptin in vivo is still under investiga-
tion, extensive characterization of its effects has been carrieddemonstrating that this proto-oncogene is involved in both pro-
liferation and survival (Roh et al., 2000). Altogether, these obser- out in cell culture. Work done using 4D5 on a panel of cell lines
that express high levels of HER-2 protein demonstrated thatvations strongly suggest that HER-2/Neu plays a direct role in
the development of mammary gland tumors. the antibody treatment led in all cases to HER-2 dephosphoryla-
tion and downregulation, but did not always result in growthThe fact that repression of HER-2 tyrosine kinase sup-
presses the malignant phenotype of cells overexpressing the inhibition. It also demonstrated that activation of EGF-receptor
family members HER-1/EGFR and HER-3/ErbB-3 and down-oncogene, together with its extracellular accessibility, has made
this protein an excellent therapeutic target. These observations stream signaling cascades could influence the overall response
S I G N I F I C A N C E
We have used mammary epithelial cells with a defined genetic alteration in a screen to isolate compounds with selective properties
against an array of transformed cells. We have taken advantage of the physicochemical properties of a small molecule to establish
its molecular mechanism of action. In addition, we have observed that a correlation exists between cellular transformation induced
by certain oncogenes and the increase in mitochondrial transmembrane potential, which serves as the selective driving force for
accumulation of the compound. Thus, this work highlights the power of cell-based assays to search for novel molecules with
therapeutic potential as well as to uncover biological properties that distinguish normal from transformed cells and that could be
exploited to target tumor cells selectively.
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of cells to HER-2 inactivation by monoclonal antibodies (Lane branes, resulting in an almost complete accumulation in the
mitochondrial matrix in response to elevated m. F16 displayset al., 2000; Neve et al., 2001). The data suggest that the activa-
tion of parallel or downstream pathways cooperating with HER-2 low intrinsic toxicity, so it perturbs mitochondrial homeostasis
only when its matrix levels are high (i.e., only at high m). Theto induce cellular transformation may override cell growth con-
trol independently of HER-2 status. In that regard, perturbation accumulation of F16 in the matrix ultimately leads to depolariza-
tion, opening of the permeability transition pore (PTP) with lossof these essential pathways instead of or in addition to targeting
HER-2 itself may provide an alternative way to inhibit propaga- of mitochondrial structural integrity, cytochrome c release, cell
cycle arrest, and death of the target cells. Finally, the selectivetion of HER-2-overexpressing cells. Furthermore, if these path-
ways are sufficiently conserved across different tumor types, effect of F16 toward neu-, ras-, and -catenin-initiated mouse
mammary epithelial tumor cell lines further suggests that a rela-they might also provide targets to inhibit the growth of many
different cancers. tionship between expression of certain oncogenes, m, and
response to DLC might exist.In an attempt to find novel approaches to identify those
poorly understood events that collaborate with HER-2 to pro-
mote cellular transformation, we screened a chemical library Results
using a modification of a cell-based assay involving BrdU incor-
poration as a measure of cell proliferation (Stockwell et al., A screen for small molecules with selective
antiproliferative activity in neu-transformed cells1999). For that purpose, we stably expressed constitutively ac-
tive neu in EpH4 mouse mammary epithelial cells (Reichmann The transforming neu cDNA (neuT ) was transfected into the
immortalized mammary epithelial cell line EpH4 (Figure 1A). Byet al., 1992). Control EpH4 and EpH4 neu-overexpressing cells
were screened in parallel. This strategy allowed discrimination Western blot analysis, an increase in the phosphorylated form
of MAP kinase and PKB was observed in the neu-overexpress-of selective inhibitors of cell growth from general cytotoxic/
cytostatic compounds. Among the small molecules isolated dur- ing cells using antibodies that specifically recognize the phos-
phorylated active form of the proteins (Figure 1B). Expressioning our screen, F16 was the most potent growth inhibitor of
the neu-overexpressing cells. Further characterization of this of neuT altered the morphology of EpH4 cells in two-dimensional
cultures (Figure 1C). In addition, neu-overexpressing cells, butcompound showed that it is selectively concentrated by mito-
chondria of various cell lines derived from mammary tumors of not EpH4 alone, formed fast-growing tumors when injected into
nude mice (data not shown). These results indicated that Neuneu and v-Ha-ras transgenic mice, but not by mitochondria
of normal mammary epithelial cells or various tumor cell lines protein was capable of active signaling and of inducing cellular
transformation in the EpH4 cells. These stably transfected cellsderived from c-myc transgenic mice.
Mitochondria have been recently recognized as integrators provided a good experimental system to utilize in a high-
throughput screen (HTS) for inhibitors that selectively interfereof a plethora of intrinsic and extrinsic apoptotic pathways (Gross
et al., 1999). Besides their role in apoptosis, mitochondria are with the proliferation of neu-overexpressing cells. A chemical
library comprised of approximately 16,000 small molecules wasessential to provide ATP for all cellular endoergonic processes.
Electrons extracted from reducing equivalents generated in the screened using the cytoblot assay. The ability of small molecules
to inhibit cell proliferation at a final concentration of 10–15 Mmatrix by the tricarboxylic acid (TCA) cycle are funneled through
the mitochondrial respiratory chain complexes to finally reduce was determined by the relative incorporation of BrdU into DNA
in EpH4-A6 (A6) neu-overexpressing and EpH4-EV (EV) controlO2. At the level of individual complexes, the transport of elec-
trons is coupled to proton pumping into the intermembrane cells. The results for one particular set of 4 plates from the 51
sets tested during the screen are shown (Figure 1D). In thisspace. As a result of this process, a characteristic negative
proton electrochemical gradient across the inner membrane is specific example, several small molecules exhibited an antipro-
liferative effect on neu-expressing cells which was indistinguish-generated. The free energy accumulated in the proton gradient
is used to generate ATP. The electrical portion of the gradient, able from that exhibited on control cells. In only one instance,
a small molecule affected proliferation of the transformed cellsthe membrane potential (m), can vary among metabolic sta-
tuses of the cell and among different cell types, tumor carcinoma in a selective manner. Several compounds, which scored as
positives during the initial screen, could be clustered into groupscells often being among those with higher mitochondrial mem-
brane potential (Bernal et al., 1982; Summerhayes et al., 1982). based on structural homologies. During a secondary screen,
the potency of these small molecules was evaluated at 1 M.Disruption of m causes secondary perturbation of ionic and
volumetric homeostasis and impedes the mitochondrial partici- Out of the six compounds selected, one that we termed F16
was capable of partially inhibiting BrdU incorporation in EpH4-pation in crucial cellular processes such as Ca2 signaling, en-
ergy production, and control of the redox state (Bernardi et al., A6 at a concentration of 100 nM in a dose-response assay
1999). The intrinsic variation of the m among cell types and (Figure 1E).
the crucial role of this parameter in mitochondrial homeostasis
provide a unique opportunity for selective drug accumulation F16 affects growth in several mouse
and human cancer cell linesinto tumor cells with potential therapeutic effect. In fact, earlier
studies have shown that the constitutively higher m of trans- The effect of F16 on a panel of mouse tumor cell lines derived
from neu, v-Ha-ras, -catenin, and c-myc transgenics and aformed cells could be used to selectively target toxic delocalized
lipophilic cations (DLCs) that accumulate in their mitochondria panel of breast human cancer cell lines was assessed. Cell lines
were scored as positives if they showed a 2–5 fold reductionin response to m (Bernal et al., 1982; Nadakavukaren et al.,
1985). in the total cell number after 3 days and 10–40 fold reduction
after 7 days. Among the mouse cell lines tested, those derivedOur results indicate that F16 is a novel and rather different
DLC characterized by very low binding to mitochondrial mem- from mammary tumors from neu and ras transgenic mice exhib-
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Figure 1. Characterization of EpH4 cells stably expressing neu and cytoblot screen
A: Whole cell lysates from starved parental EpH4, two neu-overexpressing clones (EpH4-A6 and EpH4-A8), and control cells transfected with the empty vector
(EpH-4-EV) were prepared as described in the Experimental Procedures. Equivalent amounts of proteins were resolved by SDS-PAGE and immunoblotted with
antibodies against Neu and -actin. B: Samples were further immunoblotted with antibodies against the phosphorylated forms of PKB and MAPK. C: Phase
contrast image of clones in 2D cultures. D: EpH4-EV (top) and EpH4-A6 neu-overexpressing cells (bottom) were screened in parallel using a chemiluminescent-
based assay (Experimental Procedures) for the ability of small molecules to inhibit BrdU incorporation as a measure of their growth inhibitory effect. The
autoradiograph shows one example of a set of plates from the 51 sets screened. The well highlighted in black corresponds to a small molecule with
selective antiproliferative effect on the neu-transformed cells. E: Structure of F16, the most potent inhibitor isolated during HTS.
ited a marked sensitivity for F16, while the growth of the mouse in G1 phase, as measured by FACS analysis of cells stained
for DNA content with an antibody specific for BrdU (Figure 2A).fibrosarcoma cell lines derived from ras-transgenic mice was
not affected (Table 1). In addition, we observed a moderate These results indicated that the decrease in the BrdU incorpora-
tion observed during the HTS is consistent with a cell cycleresponse in the case of -catenin-initiated mammary tumor cell
lines, while myc-initiated mouse tumor cells were F16 resistant. arrest. Cell cycle analysis performed on mouse and human cell
lines that scored sensitive to F16 in the viability assay showedEight out of the ten cell lines in the human breast cancer panel
were also affected by the small molecule (Table 1). These results a similar dramatic decrease in the number of cells in S phase
with a consistent G1 arrest for most cases, and both G1 anddemonstrated that this compound displayed antiproliferative
activity against both mouse and human breast cancer cells. A G2 in a few instances (data not shown). So in addition to the
effects observed in A6 and A8 EpH4 neu-overexpressing cells,positive correlation between the initiating oncogene in mouse
mammary epithelial tumor cells and the response to F16 was F16 induced cell cycle arrest in sensitive mouse tumor and
human cancer cell lines. Prolonged incubation with 3 M F16observed. However, the resistance of fibrosarcoma tumor cells
in the case of the ras-initiated cell lines suggests that F16 sensi- resulted in increased cell death of F16-sensitive cells but not
of F16-resistant ones. Hence, we assessed if cell death bytivity can not be simply defined on the basis of oncogene overex-
pression, but rather that other factors imposed by the cellular apoptosis followed the cell cycle arrest observed upon F16
treatment. While the EV cells were not affected, F16 causedenvironment play a major role in the outcome of the treatment.
apoptosis of A6 cells in a time-dependent manner, as judged by
oligonucleosomal DNA fragmentation (Figure 2B). The Annexin VCell cycle arrest and increased apoptosis
in F16-treated cells staining assay showed that after a 24 hr treatment with F16,
A6 cells were still viable, and that a subpopulation was alreadyBased on our results from the cell panel treatment and the
decrease in BrdU incorporation caused by F16 in neu-overex- undergoing apoptosis (Annexin V-PE positive, 7-AAD negative)
(Figure 2C). Longer incubation of A6 cells in the presence ofpressing cells by cytoblot, we examined the effect of F16 on
the cell cycle. F16 caused a dramatic decrease in the number the small molecule resulted in an increase in the Annexin V-PE
and 7-AAD positive cell population, indicative of cells in laterof cells in S phase and an increase in the percentage of cells
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due to the extended  electron system created by the link ofTable 1. Effect of F16 on mouse and human tumor cell lines
the two rings, F16 shows a lower energy absorption band in
Initiating Tissue of origin/ F16 the visible region with a maximum at 420 nm. Relaxation of theOrganism oncogene Cell line tumor type response
exited state by fluorescence is also favored by the conforma-
Mouse neu NF980 Breast  tional rigidity of the molecule, resulting in an intense emission
SMF Breast 
band at 520 nm. These properties allowed the direct visualiza-NAF Breast 
tion of F16. We have used its autofluorescence to determinen-Neu Breast 
Neu4145 Breast  the fate of the molecule inside the cell. Various cell lines incu-
NF324-2A Breast  bated with F16 for 24 hr were examined for their fluorescent
NF324-1B Breast  signal under an inverted microscope. Immortalized, nontrans-v-Ha-ras AC/Balb12 Fibrosarcoma 
formed mouse mammary epithelial cell lines like HC11, NMuMG,AC/Balb14 Fibrosarcoma 
AC/Balb6.6 Fibrosarcoma  and EpH4, human mammary epithelial MCF10A, and mouse
AC/p53 #16 Fibrosarcoma  tumor cell lines initiated by the c-myc oncogene, which are
AC/p53 #19 Fibrosarcoma  unaffected by F16, did not show any uptake/retention of the
AC260 Jaw 
compound. In contrast, the F16-sensitive EpH4 neu-overex-AC99 Neck 
pressing clones A6 and A8, and the v-Ha-ras-, neu-, andAC222 Intestinal 
AC/p53 4782 Intestinal  -catenin-initiated tumor cell lines, showed an intracellular
AC/p53 #1 Salivary  green fluorescent punctated staining pattern suggestive of F16
AC816 Breast  targeting to intracellular structures or organelles (Figures 3A–AC711 Breast 
3B). When cells were costained with specific mitochondrial andAC236 Breast 
SH1.1 Breast  lysosomal probes, the F16 fluorescence perfectly overlapped
-catenin 9281.a Breast / with the mitochondrial staining, but not with the lysosomal one
5297.B1 Breast / (Figures 4A–4B). Besides the mitochondria, some dense nuclear
5281.1 Breast /
particles, potentially the nucleoli, were also weakly stained as5297.A2 Breast /
previously reported for other lipophilic fluorescent cations suchc-myc 16MB9a Breast 
Myc 83 Breast  as Rhod2 and Mitotracker Orange (Boitier et al., 1999; Scorrano
M158 Breast  et al., 1999). These results indicated that the mitochondria were
13MA1a Breast  the major F16-concentrating organelle in the cell. Taken to-Human Unknown SKBR-3 Breast 
gether with the ability of F16 to induce cytochrome c release,T47D Breast 
ZR75 Breast  these results pointed to mitochondria as a potential site of action
BT474 Breast  for F16.
MCF-7 Breast 
MDA-MB-231 Breast 
Selective accumulation of F16 in mitochondria is drivenMDA-MB-435 Breast 
by their negative transmembrane potentialMDA-MB-436 Breast 
MDA-MB-453 Breast  As mentioned earlier, a group of molecules collectively known as
MDA-MB-468 Breast  delocalized lipophilic cations or DLCs that, like F16, selectively
, 10 fold difference in cell number. accumulate in the mitochondria of tumor cells had been pre-
/, 2- to 4-fold difference in cell number. viously described (Modica-Napolitano and Aprille, 2001). Rho-
, no difference in cell number. damine 123, the thiopyrylium AA-1, and the rhodacyanine MKT-
077 all share a highly hydrophobic structure and a delocalized
positive charge that allows for their diffusion through lipid mem-
branes and their accumulation. While chemically very different
in overall structure from these compounds, in this particularstages of apoptosis or cells that had already died. In contrast,
untreated or F16-treated control cells were primarily viable and regard, F16 resembles these DLCs.
We therefore tested whether the m was the driving forcenot undergoing apoptosis (AnnexinV-PE, 7-ADD negative).
Many intrinsic apoptotic stimuli converge on the mitochondria for F16 accumulation into the mitochondria. Preincubation of
A6 cells in medium containing carbonyl cyanide p-(trifluoro-and induce the release of cytochrome c to activate downstream
pathways of the cell death program (Liu et al., 1996). We there- methoxy)phenylhydrazone (FCCP), a protonophore that dissi-
pates the m, or valinomycin, a K-ionophore, retarded thefore measured whether F16 induced the release of cytochrome
c from the mitochondria by specific immunofluorescence. Of entry and greatly reduced the overall accumulation of F16 inside
mitochondria. Furthermore, if FCCP was added to cells pre-note, F16 induced early cytochrome c release, with loss of
loaded with F16, F16 mitochondrial staining was immediatelythe punctate mitochondrial pattern for cytochrome c and the
lost and a diffuse signal throughout the cytoplasm emergedappearance of a diffuse cytosolic staining (Figure 2D). In conclu-
instead. This suggests that the m is not only promoting F16sion, following cell cycle arrest, F16 treatment led to apoptotic
entrance but it is also acting as a retention force to drive thedeath of F16-sensitive EpH4-A6 cells, but not of F16-resistant
accumulation (Figure 5A). In addition, preincubation of cells inEpH4-EV cells.
the presence of high K medium (150 mM) to depolarize the
plasma membrane resulted in a delayed F16 appearance insideF16 is a fluorescent small molecule that
can be visualized in living cells mitochondria (data not shown). These results further suggests
that the plasma membrane, as previously observed with otherPyridinium ions and indole produce absorption and emission
bands in the UV region of the electromagnetic spectrum, but DLCs, might help to preconcentrate F16 in the cytoplasm of
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Figure 2. Cell cycle analysis and determination of apoptosis on F16-treated cells
A: Flow cytometry analysis of BrdU incorporation in EpH4-A6 and control EV cells treated with 3 M F16 for 36 hr. B: Agarose gel electrophoresis followed
by ethidium bromide staining of DNA isolated from untreated or EpH4-A6 cells treated with F16 for 48, 60, and 72 hr. C: EpH4-A6 and control EV cells
subjected to a time-course treatment with F16 were stained with Annexin V-PE in buffer containing 7-AAD and analyzed by FACS. D: Subcellular localization
of cytochrome c by immunofluorescence in untreated or F16-treated EpH4-A6 cells for 15, 24, and 48 hr.
sensitive cells, which in turn moves into the mitochondrial matrix confirming the flow cytometry analysis (Figure 5B). The protono-
phore FCCP completely abolished the punctate mitochondrialthat is at a more negative potential. Most of the currently used
fluorescentm probes are substrates for the plasma membrane pattern of TMRM to an equivalent level in A6 and EV cells,
indicating no significant differences in the binding of the probemultidrug resistance pumps that can efficiently extrude them
from the cytosol. To determine if the lack of F16 accumulation between the two cell lines (data not shown). In light of the
previous results, we concluded that there was a direct correla-inside the F16-insensitive cells was due to active extrusion by
the multidrug resistance pumps, F16-resistant immortal mam- tion between intensity of TMRM staining, i.e., resting mitochon-
drial membrane potential, F16 accumulation, and the sensitivitymary epithelial and human breast cancer cell lines were coincu-
bated with 3M F16 in the presence of 10M verapamil/100M of cells toward it.
probenecid. Under these conditions, F16 did not accumulate in
mitochondria, indicating that at least in the cell lines examined, Mitochondrial structure and function are compromised
in cells affected by F16the exclusion was not mediated by MDR-1 or MRP-1 (Lizard et
al., 1994). To test whether F16 concentration compromised mitochondrial
homeostasis, we performed electron microscopy analysis onBecause cellular accumulation of F16 appeared to be a
function of the m, and it was not influenced by multidrug untreated or F16-treated A6 cells, control cells, and two addi-
tional mouse tumor cell lines, SH1.1 and SMF. Mitochondriaresistance pumps, we compared in a semiquantitative way the
mitochondrial potential among cell lines that are sensitive or were the only organelles where ultrastructural abnormalities
were evident as early as 15 hr of F16 treatment. A6 cells showedresistant to F16. For this purpose, A6 cells, control cells, and
various mouse tumor cell lines were subjected to flow cytometric progressive swelling, disruption of the mitochondrial cristae,
and concomitant mitochondrial outer membrane rupture, whileanalysis using tetramethylrhodamine methyl ester (TMRM), a
probe whose accumulation in the mitochondrial matrix is pro- EV cells showed no lesions (Figure 6A). One of the major roles
of mitochondria is to supply energy to the cell. To assess alter-portional to the m. Nonyl-acridine orange, a probe that stains
the mitochondrial lipid cardiolipin, was used to normalize ac- ations in mitochondrial function, ATP levels were determined in
F16-treated cells by the luciferase-catalyzed ATP-dependentcording to mitochondria mass (Table 2). The results from these
experiments showed that cell lines that responded to F16 accu- bioluminescent oxidation of luciferin (Figure 6B). A significant
depletion in the ATP pool was observed in cells after 24 hr ofmulated 2.5–25 fold more TMRM than insensitive ones. In situ
mitochondrial TMRM fluorescence in neu-overexpressing cells F16 incubation. Mitochondria are the major intracellular source
of reactive oxygen species, which are expected to be moreappeared clearly higher than in the control EV cells, further
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Figure 3. Imaging F16 in living cells
A: A panel of F16-sensitive mouse mammary tu-
mor cell lines was incubated in 3 M F16-con-
taining medium for 24 hr prior to imaging. B: F16
fully resistant immortalized mouse mammary epi-
thelial and partially resistant tumor cell lines sub-
jected to identical treatment. Fluorescent F16
signal on the left; phase contrast on the right.
abundant during apoptosis and in response to mitochondrial mitochondrial membrane channel that in its open conformation
is permeable to solutes up to 1500 Da (Bernardi et al., 1999).dysfunction (Raha and Robinson, 2001). We therefore measured
the level of superoxide anion following treatment with F16. An Opening of the PTP ultimately leads to swelling of mitochondria
and has been suggested to be involved in several apoptoticincrease in superoxide production could be detected by moni-
toring the conversion of dihydroethidium to ethidium by flow pathways (Bernardi et al., 1999; Kroemer et al., 1998). To ad-
dress if F16 affected the PTP, we turned to mouse liver mito-cytometry (Figure 6C). The increase in the fluorescent signal
observed in F16-treated A6 cells but not in EV cells as a conse- chondria. Under the experimental in vitro conditions, in the ab-
quence of the resulting complex between ethidium-DNA is indic- sence of ADP, mitochondria will not use part of the proton
ative of higher levels of superoxide anion. These results are electrochemical gradient to drive ATP synthesis. This results in
in accordance with the observed F16-dependent increase in a constitutively high membrane potential that can drive F16
cellular protein carbonyl content, an indicator of protein oxida- accumulation into mitochondria. F16 caused swelling of purified
tive damage (data not shown). Since the accumulation of F16 mitochondria in a dose-dependent fashion, and cyclosporin A
in mitochondria is dependent on m, we tested whether dissi- (CsA), a specific PTP inhibitor, completely abolished this effect
pation of the membrane potential was able to interfere with F16 (Figures 7A–7B) (Broekemeier et al., 1989). It has previously
cytotoxicity. While A6 cell number dramatically decreased upon been shown that DLCs such as Mitotracker Orange can cause
F16 incubation, its proliferation rate in the presence of FCCP/ mitochondrial depolarization followed by induction of the PTP
F16 was indistinguishable from that of FCCP alone (data not (Scorrano et al., 1999). We asked whether F16-mediated PTP
shown). Our data suggested that mitochondria were likely the opening could be the result of F16-induced mitochondrial depo-
primary target for F16-mediated toxicity. F16 accumulation in larization. To address this question, we took advantage once
mitochondria induced mitochondrial damage characterized by again of the fluorescent properties of F16. Isolated mitochondria
failure to synthesize ATP, imbalance of volumetric homeostasis, build up a membrane potential in response to energization by
cytochrome c release and increased production of reactive oxy- addition of respiratory substrates. We monitored the changes
gen species. Thus, the volumetric, energetic, and redox balance in fluorescence of a 1 M solution of F16 in response to mito-
in the F16-treated cells was drastically disrupted. chondrial energization and depolarization. In response to mito-
chondrial energization, the fluorescence of the F16 solution in-
creased, whereas membrane potential dissipation by FCCPMitochondria are a direct target
for F16-mediated toxicity completely reverted this fluorescence increase (Figure 7C, black
trace). Interestingly, when mitochondria were incubated withElectron microscopy images showed that F16 induced mito-
chondrial swelling in neu-overexpressing cells. Therefore, we 30 M F16, energization led to a much smaller fluorescence
increase (Figure 7C, green trace). Preincubation of mitochondriadissected the mechanism of F16-induced swelling to under-
stand its mode of action at the molecular level. The permeability with the PTP inhibitor CsA only partially blunted this effect (Fig-
ure 7C, red trace). Thus, F16 caused depolarization of purifiedtransition pore (PTP) is a nonselective, voltage-dependent inner
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Figure 5. Effect of mitochondrial transmembrane potential (	m) on F16
mitochondrial concentration
A: Cells were preincubated in F16-containing medium for 1 hr (a) and then
treated with 5 M FCCP. Cells were photographed 1 min (b) and 3 min
(c) after FCCP addition. Nuclei were counterstained with Hoechst (d). B:
Pseudocolor-coded images of TMRM fluorescence in control EV cells (a)
and A6 cells (b). Cells were stained with TMRM and imaged as described
in the Experimental Procedures.
At higher concentrations, this increase in mitochondria ener-
gized with complex I substrates dropped in a CsA-sensitive
fashion. This is due to loss of pyridine nucleotides from the
mitochondrial matrix as a consequence of PTP opening rather
Figure 4. Colocalization of F16 and mitochondrial specific probe
than a direct effect of F16 on electron transfer, since no decrease
A: EpH4-A6 cells were coincubated as described under “Experimental Pro- in respiration was observed when mitochondria were energized
cedures” with F16 (a) and Mitotracker Red (b) and the images overlaid (c).
with succinate (which feeds electrons directly to complex II,Nuclei were stained with Hoechst (d). B: Same as A, but with Lysotracker
bypassing the need for pyridine nucleotides) (Figure 7D). Thus,Red instead of Mitotracker Red.
our results indicate that F16 affects mitochondrial respiration,
inducing an increase rather than a decrease in basal respiratory
rate that would be expected following inhibition of the respira-
mitochondria. This depolarization led to opening of the PTP, tory chain. Small perturbations on the electron transfer chain
further increasing the dissipation of m. Next, we investigated do appear manifest when measuring the basal respiratory rate,
the mechanism of the observed depolarization. In principle, mi- and they may become evident when electron transfer along
tochondrial depolarization could be caused by a direct protono- the respiratory chain is maximized, i.e., when mitochondria are
phoric effect, i.e., by protons shuttling across the inner mito- uncoupled. For this purpose, we determined the effect of F16
chondrial membrane, or indirectly as a consequence of inhibition on uncoupled respiration. The uncoupler FCCP was added to
of the respiratory chain. To dissect this, we assessed the effect mitochondria 3 min after F16, and the rate of uncoupled respira-
of F16 on mitochondrial respiration by measuring mitochondrial tion was measured. Increasing concentrations of F16 caused
O2 consumption. In vitro, mitochondria respond to membrane a progressive inhibition of the uncoupled respiration, irrespec-
depolarization by increasing their basal (state 4) respiratory rate. tive of the respiratory substrate used. The PTP inhibitor CsA
completely abolished this effect (Figure 7E). Thus, the respira-F16 caused an increase in state 4 respiration in mitochondria
incubated with substrates for complexes I and IIIII (Figure 7D). tory inhibition does not appear to be due to a direct effect of
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lowed by ionic imbalance, swelling, cytochrome c release, andTable 2. Comparison of 	m in F16-sensitive and resistant cells by flow
inhibition of mitochondrial respiration, consistent with the phe-cytometry analysis of TMRM staining
notypes observed in vivo.Mitochondrial Mitochondrial
Since F16 causes PTP opening in isolated mitochondria,potential log mass NAO ratio TMRM/NAO
Cell line TMRM emission (a.u.) 530 nm/630 nm ratio we asked whether the PTP inhibitor CsA prevented F16-induced
mitochondrial toxicity in A6 cells. CsA blocked mitochondrialImmortal
swelling and cytochrome c release induced by F16. As ex-
EpHr 37 3.10 11.94 pected, since the inhibitory effect of CsA on the PTP is transient,EpH4-EV 199 2.76 72.10
the protection became increasingly weaker upon prolonged F16HC11 118 2.77 42.60
NMuMG 33 3.17 10.41 incubation (data not shown). Taken together, these results sug-
gest that the mitochondrial dysfunction induced by F16 is re-c-myc
lated to induction of the PTP.
13MA1a 269 2.94 91.50
16MB9a 240 2.80 85.71
Neu-dependent signaling is turned off
neu in F16 treated cells
EpH4-A6 462 1.78 259.55 In parallel to the characterization of the effect of F16 on mito-
EpH4-A8 466 1.72 270.93 chondria homeostasis, we investigated the effect of F16 on
SMF 875 2.89 302.77
cell signaling. A decrease in phosphotyrosine content of Neu,NAF 761 2.58 294.96
phosphorylated PKB/Akt, and phosphorylated MAP kinase were
v-Ha-ras observed. As a consequence of F16 treatment, Neu and PKB
AC816 726 3.36 216.07 protein levels were reduced (Figure 8). Previous studies have
SH1.1 648 3.45 187.83 shown that Neu and PKB/Akt are substrates for caspase-medi-
ated cleavage (Bachelder et al., 2001; Tikhomirov and Carpen-
ter, 2001). Therefore, we tested whether this downregulation
was blocked by the broad-spectrum caspase inhibitor zVAD-
fmk. zVAD-fmk only partially inhibited Neu and PKB/Akt down-F16 on electron transfer, but rather the consequence of F16-
regulation (data not shown). Given the profound mitochondrialinduced PTP opening, which includes secondary swelling and
dysfunction that accompanies F16-induced cytochrome c re-release of the respiratory chain component cytochrome c. Taken
lease, the only partial zVAD-fmk protective effect could be thetogether, these results show that F16 acts as a weak protono-
result of an increase in degradation of proteins that have under-phore and that it lowersm. This depolarization results in open-
ing of the voltage-dependent PTP. Opening of the PTP is fol- gone oxidative damage. A limited cellular ATP supply leads to
Figure 6. Structural-functional alterations in mitochondria of F16-treated A6 cells
A: Electron microscopy was performed on ultrathin sections of A6 untreated (a) or treated with F16 for 15, 24, 36, and 48 hr (b–e). Control EV cells were
treated with F16 for 48 hr (f). Normal and abnormally swollen and apoptotic mitochondria in the case of F16-treated A6 cells are marked with black arrows.
B: Quantification of ATP levels by luciferin-luciferase assay in F16-treated EpH4-A6 cells (black) and EV cells (gray) as described under Experimental
Procedures. Control FCCP-treated A6 cells (hatched). C: Comparison of reactive oxygen intermediate levels in F16-treated EpH4-A6 (circles) and EpH4-
EV (triangles) cells. Flow cytometry analysis of ethidium bromide-DNA fluorescence resulting from dihydroethidium oxidation as a measure of superoxide
levels.
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Figure 8. Effect of F16 on Neu activation and downstream signaling
Control and neu-overexpressing EpH4-A6 cells were left untreated or
treated with 3 M F16 for 24 and 48 hr. Whole cell lysates were prepared
as described (Experimental Procedures). Samples were immunoblotted with
antibodies against Neu, PKB, and MAPK, as well as antibodies that react
with the phosphorylated forms of the proteins. Samples were probed with
anti--actin as loading control.
Figure 7. Effect of F16 on isolated mitochondria
A: Effect of F16 on mitochondrial volume. 0.5 mg/ml mitochondria were
incubated in experimental buffer. Where indicated, 10 M Ca2, 0.5 mM
EGTA (a Ca2 chelator used to synchronize PTP opening in population of decrease in overall protein synthesis, an ATP-dependent pro-
isolated mitochondria) opening, and F16 were added. If indicated, 1 M cess. These two effects combined may affect the steady-state
CsA was added prior to mitochondria suspension. B: Dose dependence of
level of proteins in a differential manner, depending on theirpermeability transition pore induction by F16. The experiment was con-
particular turnover rates, since MAPK and -actin levels wereducted as in A. C: Effect of mitochondrial energization on F16 fluorescence.
0.5 mg/ml mitochondria were incubated in experimental buffer supple- not affected. Regardless of the mechanism behind F16-medi-
mented with 2 M rotenone and 1 M (black trace) or 30 M (red and ated protein downregulation and dephosphorylation, the net
green traces) F16. Green trace, 2 M CsA was present from the beginning. effect is inactivation of major pathways involved in proliferation
Where indicated, 5 mM succinate and 200 nM FCCP were added. Note
and survival, further contributing to the inhibition of cell growth.that mitochondrial energization causes an increase in the fluorescence of
F16. D: Effect of F16 on basal (state 4) respiratory rate. Mitochondria (1 mg/
ml) were incubated in experimental buffer supplemented with substrates Discussion
for the individual respiratory complexes. Oxygen consumption was deter-
mined as described in the methods section. Where indicated, mitochondria
The goal of the chemical screen performed was to use an unbi-were incubated with 1 M CsA for 2 min before F16 addition. Respiratory
ased assay and to identify novel small molecules that couldrates are normalized to the rate of untreated mitochondria. Maximum rate
of oxygen consumption (state 4): complex I (glutamate/malate), 10.3
 1.1 selectively inhibit the growth of neu-overexpressing cells, in
nAt/mg/min; complex IIIII (succinate), 19.6 
 2.1 nAt/mg/min; complex order to gain insights into the process of cellular transformation
IV (ascorbate/TMPD), 110.4
 6.7 nAt/mg/min. E: Effect of F16 on uncoupled driven by this oncogene. These studies led to the isolation of
respiratory rate.1 mg/ml mitochondria were treated with 200 nM FCCP and
F16, a small molecule that selectively targets neu-overexpress-3 min later with the indicated concentration of F16. Respiratory rates are
ing mammary epithelial cells. Further characterization of theplotted as the percentage of the maximum rate (in the presence of FCCP
alone). Maximum rate of oxygen consumption (uncoupled): complex I, compound showed a broader spectrum of action. In addition
61.8 
 4.3 nAt/mg/min; complex IIIII, 127.4 
 5.3 nAt/mg/min; complex to mouse mammary tumor cell lines overexpressing neu, mouse
IV, 132.5 
 5.1 nAt/mg/min.
mammary tumor cell lines overexpressing v-Ha-ras and
-catenin, but not c-myc, and human breast tumor cell lines of
a diverse nature were growth inhibited as well. Unlike our mouse
mammary tumor cells lines, the initiating event in the human
breast cancer cell lines analyzed is undefined, which makes
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correlations of F16 sensitivity harder to establish. Although established the anticarcinoma activity of systemically adminis-
tered DLCs against various tumor cell lines implanted in nudeSKBR-3, BT474, and MDA-MB-453 express HER-2 at high lev-
els, the growth inhibitory effect of F16 was not limited to them. mice (Chiba et al., 1998; Koya et al., 1996; Sun et al., 1994).
The potential of MKT-077 as a new antineoplastic compoundFor example, cell lines like MCF-7, T47D, or MDA-MB-468,
with moderate to undetectable levels of HER-2 compared to was recently evaluated. Although the phase I trials were discon-
tinued due to renal toxicity, both studies established that MKT-immortal mammary epithelial cells, were F16 sensitive as well.
These same cell lines have been shown to overexpress various 077 was preferentially accumulated in tumor cell mitochondria
(Britten et al., 2000; Propper et al., 1999). Because in principlecombinations of EGF receptor family members, which could
explain, in part, their sensitivity toward F16 (Moasser et al., DLCs behave as expected in vivo, these results further empha-
size the need for novel DLCs with higher therapeutic effective-2001). Our interpretation of the results in mouse and human
cell lines is that transformation mediated by neu, as well as ness. Our results showed that intraperitoneal injection of 20 mg/
kg of F16 retarded the growth of A6-derived subcutaneousother oncogenes like v-Ha-ras, -catenin, and potentially EGF
family members, among others, could induce the changes that tumors in nude mice (V.R.F. and P.L., unpublished data). Thus,
F16 might hold therapeutic potential as anticancer reagent.render cells responsive to F16.
Based on the fluorescent properties of F16, we were able Our screen has not only identified a novel small molecule
with selective activity toward transformed cells, but it has identi-to identify the mitochondria as the major concentrating organelle
in the cell. This observation and the fact that F16 is a lipophilic fied the mitochondria as a compartment that is affected by neu
overexpression. Using a panel of characterized mouse tumorsmall molecule with delocalized positive charge suggested that
it is a member of the DLC group of small molecules. This group cells, we could correlate increased m to the specific trans-
forming oncogene. neu-, v-Ha-ras-, and -catenin-initiated tu-of mitochondriotoxic compounds has been defined empirically.
The structural diversity among DLCs is striking and, to date, mors cells and neu-overexpressing EpH4 cells presented higher
m than c-myc-initiated tumor cell lines and nontransformedthe properties that make each DLC a good antiproliferative agent
are still poorly understood. At high concentration, these mole- mammary epithelial cell lines. We have focused our efforts
mainly on four oncogenes, and from that point of view, thesecules display mitochondrial toxicity, although their targets are
quite different. For instance, the toxic effects of rhodamine 123 are just examples of genetic alterations leading to changes in
m. Prior to our analysis, chemically induced cellular transfor-and dequalinium chloride have been linked to their ability to
inhibit F0-F1 ATPase and NADH-ubiquinone reductase activity, mation and overexpression of v-fos in rat fibroblasts are the
only examples of a causal relationship between the initial trans-respectively (Anderson et al., 1989, 1993; Modica-Napolitano
and Aprille, 1987; Modica-Napolitano et al., 1984). Likewise, forming event and the increase in m (Liang et al., 1999; Sum-
merhayes et al., 1982; Zarbl et al., 1987).MKT-077 toxicity has been associated with both MKT-077-
driven mitochondrial DNA depletion and a general destabiliza- To date, there is no clear understanding of what the key
factors that contribute to differences in the magnitude of mtion of the mitochondrial inner membrane (Modica-Napolitano
et al., 1996). between tumor cells and their normal counterparts are. In a few
cases, a link between oncogene expression and changes in theGiven their higher m, mitochondria of tumor cells specifi-
cally accumulate DLCs. Normal cells, on the other hand, pos- expression level of mitochondrial genes has been established
(Ohnami et al., 1999). Thus, the variation of m could simplysess moderate m and fail to accumulate this class of com-
pounds. F16 causes mitochondrial dysfunction as judged from come from differences in proteins involved in the respiratory
chain or those that form the mitochondrial PTP (Modica-Napo-our studies in cells or with purified mitochondria. Our results
indicate that F16 is capable of slowly dissipating the proton litano and Aprille, 2001). On the other hand, differences in m
could be the consequence of metabolic adaptations that cellsgradient established across the inner mitochondrial membrane.
The decrease in the m can in turn be sensed by the PTP, a undergo during the process of cellular transformation (Dang and
Semenza, 1999). It has been known since the 1930s that tumorvoltage-dependent inner membrane channel (Scorrano et al.,
1997). Opening of the PTP leads to an increase permeability cells maintain higher rates of anaerobic glycolysis even in the
presence of high pO2 levels (the so-called Warburg effect) (War-to small solutes and dissipation of ionic gradients, swelling,
inhibition of respiration, disruption of redox homeostasis, and burg, 1956). Mitochondria generate ATP using the proton elec-
trochemical gradient across their inner membrane. In theory,release of apoptogenic factors, committing the cell to apoptotic
death. We assessed whether F16 retained its ability to induce the inability of tumor cells to use mitochondria to fulfill all their
ATP demands (i.e., dissipation of a smaller fraction H) evenapoptosis in cells lacking bax/bak (DKO) that are resistant to
a panoply of apoptotic inducers (Wei et al., 2001). F16 was when oxidative phosphorylation is not limited by the low pO2
could explain why tumor cells display higher m. A systematicaccumulated to similar levels in both cell lines, and induction
of apoptosis was comparable in the two genotypes (data not biochemical characterization of the mitochondrial protein profile
of normal and transformed cells will provide us with clues toshown). Our results from studies in isolated mitochondria and
cells suggest that F16 toxicity is mediated, at least in part, by understand the basis for the altered m in tumor cells and the
correlation to oncogene overexpression. Knowing what proteinsthe PTP. Nevertheless, our studies do not exclude the possibility
that in cells the prolonged, high local concentration of F16 within to inactivate in mitochondria of tumor cells, a target-limited
search for compounds in a small molecule database could leadthe mitochondrial matrix could affect the organelle at multiple
levels. Thus, it is possible that F16, besides causing PTP open- to more effective DLCs or to molecules that could be chemically
modified to include the desired properties. In addition, if it wereing, could be producing several parallel mitochondrial lesions
that collectively induce cell death. possible to transiently modulate the m, drug targeting could
be improved and undesired side effects minimized.In addition to the effect of F16 on tumor cell lines in culture,
we also tested the effect of F16 in vivo. Several studies have Our analysis also suggests that in neu-overexpressing cells,
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to the medium, while control cells were left untreated. Cells were countedF16 was capable of neutralizing Neu activity and downstream
3 days and 7 days after initiation of treatment. Counts were done in triplicatesignaling. It is quite possible that this effect is secondary to the
for untreated and F16-treated cells.mitochondrial damage imposed by the small molecule, since
no direct interaction between F16 and Neu was detectable in
Cell lysate preparation and immunoblotting
Neu pull-down experiments (data not shown). Nevertheless, the EpH4, EpH4-A6, and EpH4-A8 were incubated in serum-free medium for 5
growth promoting activity of the receptor could be blocked by hr where indicated. Otherwise, cells were washed with PBS and lysed in
F16 without specifically targeting the protein. lysis buffer (40 mM HEPES, 150 mM NaCl, 10 mM sodium pyrophosphate,
Finally, the fact that F16 specifically targets the mitochondria 2% Nonidet P-40, 10 mM NaF, 2 mM EDTA, and 5 M Na3VO4) containing
Complete protease inhibitor cocktail (Roche). The lysates were spun atis of particular interest. Recently, attention has been drawn
140,000 g for 30 min. to separate the insoluble material. Protein concentra-to mitochondria as potential targets of anticancer therapy, in
tion was determined on the supernatants using Bradford reagent (Bio-Rad).particular because of their pivotal involvement in cell death (Cos-
An aliquot of each lysate containing equivalent amounts of protein wastantini et al., 2000). As the molecular dissection of the apoptotic
separated by SDS-PAGE and transferred to Immobilon-P membranes (Milli-
pathway proceeds, the crucial role of mitochondria in propagat- pore). The transfer buffer consisted of 25 mM Tris, 190 mM glycine, 20%
ing the cell death signal becomes clearer (Green and Reed, methanol, and 0.005% SDS. Membranes were blocked with 1.5% BSA in
1998). Inactivation of the tumor suppressor p53 and overexpres- TBST (150 mM NaCl, 20 mM Tris-HCl [pH 7.4], and 0.3% Tween 20), and
sion of the oncogene bcl-2 are common traits in several neopla- the primary antibodies (1 g/ml) and secondary antibodies were in 0.2%
BSA in the same buffer. Membranes were washed with TBST buffer. In allsias, conferring resistance to several apoptotic stimuli (Cheng
cases, blots were developed with horseradish peroxidase conjugated toet al., 2001; Korsmeyer et al., 1990; Somasundaram, 2000).
anti-rabbit IgG or to anti-mouse IgG (Amersham). The enhanced chemilumi-Thus, therapeutic interventions that can selectively target the
nescence reagent (Pierce) was used for detection.mitochondria of transformed cells and trigger the apoptotic cas-
cade without relying on intact upstream apoptosis-inducing
Cytoblot
pathways could represent a specific, low toxicity approach in A modified version of a protocol previously described was used for the
cancer treatment. cytoblot assay (Stockwell et al., 1999). Briefly, for this cytoblot assay, 2,000
control (EpH4-EV) and Neu overexpressing (EpH4-A6) cells in 40 l of grow-
Experimental procedures ing medium were seeded in duplicate in each well of a white 384-well plate
(Costar). 16,000 compounds from a chemical library (ChemBridge) were
Reagents transferred to each well to a final concentration of 10–15 M. Plates were
Anti-phospho Neu, anti-Neu, and anti-pTyr were purchased from Upstate incubated at 37C with 5% CO2 for 36–40 hr. BrdU was then added to aBiotechnology Inc. Anti-phospho MAP kinase, anti-PKB, and anti-phospho
final concentration of 20 M and the cells were incubated at 37C with 5%
PKB were purchased from New England Biolabs. Anti-ERK-1 was obtained
CO2 for an additional 3 hr. Cells were then washed with PBS and fixed withfrom Santa Cruz. F16 was obtained from Interbioscreen and Asinex, and
75% ethanol/25% TBS at 4C for 1 hr. DNA denaturation was achieved bythe stocks combined and used where indicated in subsequent experiments.
incubation with 2 M HCl/0.5% Tween-20 for 20 min, followed by neutraliza-
tion with 2 M NaOH in Hank’s Balanced Salt Solution (HBSS). Cells wereCell culture and generation of stable cell lines
subsequently washed with HBSS, blocked with PBS/0.3% Tween-20/EpH4 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM),
1%BSA (PBSTB), and incubated with 0.5g/ml of mouse anti-BrdU antibody10% FBS at 37C/5% CO2. EpH4 cells stably expressing neu were estab-
(PharMingen) and 1:5,000 dilution of anti-mouse IgG coupled to HRP inlished. The neu transforming oncogene (neuT) cDNA was subcloned into
PBSTB for 1 hr at room temperature. Finally, the cells were washed withpRETRO-OFF (Clontech) as follows. A SalI/XhoI/HindIII/NotI adaptor was
PBS, and 20 l of 1:1 mix of the enhanced chemiluminescence reagentintroduced into pBluescript (Stratagene). The HindIII/SalI fragment con-
(Pierce) was then added to each well of a plate. Addition of reagents wastaining full-length neuT cDNA was excised from a vector which itself was
done using a multidrop 384 liquid dispenser (Labsystems), and the washesderived from pSV2neuNT and inserted into corresponding sites in p-Blue-
were done using a plate washer (Bio-Tek Instruments). Chemiluminescentscript (Bargmann et al., 1986). Finally, the chimeric vector carrying neuT
cDNA was subjected to restriction digestion with NotI, and the excised 5 signal from each plate was detected by autoradiograph and multilabel
kb fragment including the neuT cDNA was introduced into the NotI site in counter Victor2 (Wallac) in order to quantitate results.
pRETRO-OFF. Transfection of EpH-4 cells was done using Fugene Reagent
according to manufacturer’s protocol (Boehinger Mannheim). Finally, stable Cell cycle analysis by flow cytometry
clones were isolated by selection in medium containing puromycin (1.2 g/ EpH4-EV, EpH4-A6, and various mouse tumor cell lines were incubated with
ml). All the clones isolated showed constitutive level of Neu protein. No 3 M F16 for approximately 36 hr. In the case of human breast cancer cell
significant repression of Neu expression was observed upon doxycycline lines, incubation with F16 was extended for a day, to a total of 3 days. Cells
treatment. were next pulsed with BrdU (20 M) for 1 hr and then fixed in 70% ethanol
at 20C overnight. The next morning, DNA was denatured in 2N HCl/0.5%
Effect of F16 on cell proliferation TritonX-100. This procedure was followed by 2 washes 0.1 M Na2B2O7,neu-initiated mouse tumors cell lines NF980, NF324-2A, NF324-1B, SMF,
and 1 wash with PBS. Cells were resuspended in residual PBS, incubated
NAF, n-Neu, and Neu4145, v-Ha-ras-initiated tumor cell lines SH1.1, AC236,
with 20 l of anti-BrdU/FITC (Becton Dickinson) for 1 hr, and subsequently
AC711, AC816, ACp53#1, ACp53#4782, AC222, AC99, AC260,
washed 1 with PBS and resuspended in residual PBS. RNA was digestedACp53#19, ACp53#16, AC/Balb6.6, AC/Balb14, and AC/Balb12,
with RNaseA (1 l of 10 mg/ml stock) at 37C for 30 min. Finally, cells were-catenin-initiated tumor cell lines 5297.B2, 5281.1, 9281.a, and 5297.B1,
diluted with 1 ml of 5 g/ml propidium iodide/PBS and incubated for on iceand c-myc-initiated tumor cell lines 16MB9a, 13MA1a, Myc 83, and M158
for 15 min. The labeled cells were analyzed using the FACSCalibur (Becton-were used to test the antiproliferative effect of F16. All these cell lines have
Dickinson).been established in our laboratory from tumors dissected from v-Ha-ras-,
neu-, c-myc-, and -catenin-transgenic mice.
Detection of apoptosis by Annexin V stainingHuman breast cancer cell lines MDA-MB231, MDA-MB435, MDA-
EpH4-A6 and EpH4-EV cells untreated or treated with 3 M F16 for 24, 48,MB436, MDA-MB453, MDA-MB-468, SKBR-3, MCF-7, T47D, and ZR-75-1
and 72 hr were stained for 15 min with AnnexinV-PE conjugate in conjunctionand mouse mammary epithelial cell line NMuMG obtained from the ATCC
with the vital dye 7-amino-actinomycin D (7-AAD) following manufacturer’swere used to test the antiproliferative effect of F16.
procedure (PharMingen). The labeled cells were analyzed using the FACS-For quantitation purposes, for each cell line, 1  105 cells were seeded
in each well of a 6-well plate. On the following day, 3 M F16 was added Calibur (Becton-Dickinson).
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DNA fragmentation Electron microscopy
DNA was isolated from 1  106 of untreated or F16 treated for 48, 60, Cells grown in 35 mm dishes were left untreated or treated with 3 M F16
and 72 hr using Suicide-Track (Oncogene) according to manufacturer’s for the indicated times, and fixed for 1 hr at room temperature in 0.1 M
procedure. Samples were resolved by agarose gel electrophoresis and ethid- Cacodylate buffer containing 1.25% formaldehyde, 2.5% glutaraldehyde,
ium-bromide stained. and 0.3% picric acid. Samples were then treated with 1% osmiuntetroxide/
1.5% potassiumferrocyanide followed by 1% uranyl acetate, dehydrated,
and epon-araldite embedded. Ultrathin sections were examined using aCytochrome c release by immunofluorescence
Untreated or F16-treated A6 cells were washed and fixed with ice-cold 3.7% JEOL 1200EX microscope. For the analysis of the effect of CsA on F16-
paraformaldehyde at RT, permeabilized with ice-cold 0.01% (v/v) Nonidet induced swelling, A6 cells were incubated in the presence of 10 M F16
P-40 for 20 min, and incubated with 0.5% BSA/PBS for 15 min. Immunode- and 10 M CsA replenished into the medium every 30 min.
tection was performed with monoclonal anti-cytochrome c antibody (Phar-
Mingen) and TRITC-conjugated anti-mouse secondary antibody (Jackson Determination of ATP
ImmunoResearch) in PBSTB. Cells were photographed under Axioskop mi- Cellular ATP levels were determined by luciferin-luciferase method using the
croscope using a Spot Camera (Diagnostic Instruments). For the analysis ATP Bioluminescence Assay Kit (Roche). EpH4-EV and EpH4-A6 cells were
of the effect of CsA on F16-induced cytochrome c release, A6 cells were grown in the absence or in the presence of 3 M F16 for 15 and 24 hr. As
incubated in the presence of 10 M F16 and 10 M CsA replenished into a control, A6 were treated with 5 M FCCP (Sigma) for 24 hr. Cells were then
the medium every 30 min. harvested and equivalent numbers of cells were used for each determination,
according to manufacturer’s procedure. Each determination was done in
Localization of F16 in living cells triplicate, and the entire experiment was performed twice.
Cells grown on 60 mm plates were incubated with medium alone or medium
containing 3 M F16 for 24 hr at 37C. The fluorescent signal of F16 was
Measurement of intracellular superoxide anion
visualized under an Axiovert inverted microscope (Zeiss) using a standard
Changes in the levels of intracellular oxidants were investigated using the
fluorescein filter set and cells were photographed using a digital camera
fluorescent probe dihydroethidium (DHE) (Molecular Probes). Superoxide
(Nikon D1).
anions can oxidize DHE to ethidium bromide (EtBr), which binds to DNA.
Alternatively, for colocalization experiments, cells were treated as fol-
An increase in the fluorescence of EtBr/DNA is suggestive of superoxide
lows. 2  104 EpH4-EV and EpH4-A6 cells were seeded in 4-well chamber
generation (Vanden Hoek et al., 1998). EpH4-EV and EpH4-A6 cells were
slides. The next morning, cells were left untreated or were treated with F16
grown in the absence or in the presence of 3 M F16 for 15, 24, 48, and
at 3 M for 2 hr. A mitochondrial specific stain, Mitotracker Red (Molecular
72 hr cells were resuspended and diluted to 106 cells/ml. DHE was added
Probes), was added to the medium to stain mitochondria, or Lysotracker
to the cell suspension to a final 2 M in each case. Cells were incubatedRed (Molecular Probes) to stain lysosomes and acidic compartments ac-
at 37C for 15 min and immediately analyzed by flow cytometry using thecording to manufacturer’s procedure. Hoechst stain was also included in
Epics Altra (Beckman-Coulter).the medium to stain nuclei. Cells were photographed as previously described
using an (100) immersion oil objective (Zeiss). The effect of the protono-
Isolation of mitochondria, mitochondrial swelling membranephore FCCP (Sigma) on F16 accumulation was performed as previously
potential, and respiration determinationdone for colocalization experiments. EpH4-A6 cells preincubated with F16
Mitochondria were isolated from livers of Balb/c7 mice by standard differen-(3 M) were subsequently treated with 5 M FCCP. Images were acquired
tial centrifugation, and resuspended in isolation buffer (0.2 M sucrose, 10immediately before and 1 min and 5 min after FCCP addition.
mM Tris-MOPS [pH 7.4], 0.1 mM EGTA-Tris, and 0.1% delipidated BSA)
(Costantini et al., 1995). For swelling determination, changes in side scatterDetermination of mitochondrial potential and mitochondrial mass
at 545 
 2.5 nm of a 0.5 mg/ml suspension of mitochondria in experimentalThe mitochondrial membrane potential of various mouse cell lines was com-
buffer (125 mM KCl, 10 mM Tris-MOPS [pH 7.4], 1 mM Pi, 5 mM glutamate,pared by flow cytometry, using the potentiometric probe tetramethylrhoda-
2.5 mM malate, and 10 M EGTA-Tris [pH 7.4]) were monitored by using amine methyl ester (TMRM, Molecular Probes) (Scaduto and Grotyohann,
LS-50B spectrofluorimeter. To monitor changes in mitochondrial membrane1999). In all cases, cells were harvested and resuspended at 1 106 cells/ml
potential, we took advantage of the intrinsic potentiometric properties ofin cell culture medium containing 10 M verapamil and 100 M probenecid
F16. Mitochondria (0.5 mg/ml) were incubated in experimental buffer with(SIGMA) and MDR-1 and MRP-1 inhibitors respectively. TMRM was added
the indicated concentrations of F16, and changes in F16 fluorescence inten-to each tube to a final concentration of 50 nM. Cells were incubated at 37C
sity were measured using a LS-50B spectrofluorimeter at 25C, with excita-for 20 min and immediately analyzed by flow cytometry. In addition, cells
tion and emission wavelengths set at 415 
 2.5 nm and 520 
 5 nm,were stained with nonyl-acridine orange (NAO) in order to estimate the
respectively. All measurements were performed at 25C, and the instrumentmitochondrial mass in the cell lines probed with TMRM (Hiura et al., 2000).
was equipped with magnetic stirring.1  106 cells/ml cells were incubated with 2 M NAO for 20 min at 37C.
Oxygen consumption was determined using a Clarke-type oxygen elec-The fluorescent emission of NAO at 530 nm and 630 nm was collected. The
trode equipped with thermostatic control and magnetic stirring. Mitochondriaratio of green to red fluorescence best reflects the cardiolipin content of
(1 mg/ml) were incubated in experimental buffer supplemented with sub-mitochondria.
strates for each respiratory chain complex as indicated in Figure 6: 5 mM
glutamate plus 2.5 mM malate for complex I, 5 mM succinate-Tris in theImaging of mitochondrial membrane potential
presence of 2 M rotenone for complex IIIII, 3 mM ascorbate plus 150For imaging of mitochondrial membrane potential in situ, A6 and control
M TMPD in the presence of 1 g/ml antimycin A for complex IV.cells were seeded onto 25 mm round glass coverslips at a density of 104
cells/coverslip and grown for 2 days prior to measurement. Cells were then
Acknowledgmentsstained with 20 nM TMRM dissolved in Hank’s balanced salt solution (HBSS)
with 10% FCS, 10 mM HEPES, and 5 M verapamil (Sigma) for 20 min at
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lines. Dr. Aya Leder and Dr. Jennifer Michaelson have kindly provided severalat 530 
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of the tumor cell lines tested. We are also grateful to Dr. Randall King foremitted light was collected using a 560 longpass filter. Digital images were
his advice during the HTS and to Dr. Nicholas Chester and Dr. Robert Weissacquired with exposure times of 30 msec using a 60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